Buy Cartalax Peptide Online | AED Tripeptide | Khavinson Cartilage Bioregulator | ≥99% Purity | CoA | SourceTides

Buy Cartalax Peptide Online from SourceTides.
Cartalax (AED; T-31; Ala-Glu-Asp) is a synthetic tripeptide bioregulator developed within the Khavinson peptide research programme at the St. Petersburg Institute of Bioregulation and Gerontology — the same programme that produced Epithalon, Thymalin, and Pinealon.

The Ala-Glu-Asp sequence is derived from the alpha-1 chain of type XI collagen and was also isolated from kidney-derived polypeptide extracts.
This structural origin in cartilage-specific collagen explains Cartalax’s tissue selectivity: chondrocytes, cartilage extracellular matrix, and fibroblasts are its primary cellular targets.

Cartalax operates through a mechanism distinct from conventional receptor-coupled peptides.
Published Khavinson laboratory data indicates that the AED sequence binds directly to the minor groove of DNA chromatin — specifically interacting with regulatory sequences of genes governing chondrocyte-specific extracellular matrix production.
This epigenetic-like transcriptional mechanism is the defining pharmacological feature that distinguishes the entire Khavinson bioregulator class from growth factors, receptor agonists, and signalling cascade modulators.

Key documented effects include: Ki-67 upregulation (cell proliferation); p53, p16, p21 downregulation (senescence pathway suppression); caspase-3 reduction (anti-apoptotic); SIRT6 upregulation (longevity sirtuin); MMP-9 downregulation (anti-catabolic ECM protection); collagen type II and aggrecan upregulation; and IGF-1 expression increases of 3.5–5.6× in aging fibroblast cultures.
Every SourceTides vial is lyophilised, tested at ≥99% HPLC purity, and ships with a full lot-specific Certificate of Analysis.
For in-vitro laboratory research use only. Not for human consumption.

Cartalax Peptide — Technical Specifications

What Is Cartalax?

Cartalax is a member of the Khavinson peptide bioregulator class — one of the most extensively documented series of short-chain peptide tissue regulators in gerontological research, developed over more than four decades at the St. Petersburg Institute of Bioregulation and Gerontology under Professor Vladimir Khavinson.
Other members of this family include Epithalon (pineal bioregulator; telomerase activator), Thymalin (thymic immune bioregulator), and Pinealon (CNS neuroprotective EDR tripeptide).

The defining feature of Khavinson bioregulators is their proposed mechanism: rather than activating cell-surface receptors or inhibiting specific enzymes, these short peptides are hypothesised to enter the cell nucleus and bind the minor groove of DNA at specific regulatory sequences.
In the case of Cartalax (Ala-Glu-Asp), the target sequences are particularly associated with the regulatory regions of genes governing cartilage extracellular matrix production — collagen type II, aggrecan, and other chondrocyte-specific matrix proteins.
This transcriptional epigenetic-like mechanism explains both the tissue specificity and the sustained nature of the gene expression changes observed in published assays.

The AED sequence is not arbitrary.
It corresponds to a fragment found in the alpha-1 chain of type XI collagen — the collagen isoform most important for maintaining cartilage architecture and regulating fibril diameter.
Type XI collagen is predominantly expressed by chondrocytes, which explains why a peptide derived from its sequence preferentially activates chondrocyte-specific gene expression programmes.
The sequence was also isolated from polypeptide fractions of calf kidney extracts, establishing its endogenous-like character.

When you buy Cartalax Peptide from SourceTides, you receive ≥99% HPLC-pure H-Ala-Glu-Asp-OH with identity confirmed by ESI-MS (MW 333.29 Da) and full lot-specific CoA.

The Khavinson Bioregulator Programme: Scientific Context

Understanding Cartalax requires understanding the Khavinson bioregulator framework, because the methodology is unusual by Western peptide research standards.

The programme began in the 1970s with the observation that tissue-specific polypeptide extracts from young animals could restore cellular function in older animals of the same species.
The working hypothesis was that short peptide fragments — liberated from tissue proteins during normal turnover or in response to stress — acted as informational molecules that could directly reset gene expression programmes in target cells.
Rather than ligand-receptor signalling, the proposed mechanism was nuclear: these peptides enter cells, access chromatin, and bind to regulatory DNA sequences associated with tissue-specific gene expression.

Cartalax (AED) was identified by fractionating kidney-derived polypeptide extracts and testing individual fractions for their ability to stimulate chondrocyte proliferation and reduce senescence markers.
The AED tripeptide was one of the active components identified.
Its sequence was subsequently confirmed to appear in the alpha-1 chain of type XI collagen, establishing the biological rationale for its cartilage-cell targeting.

The direct evidence for DNA minor groove binding comes from biophysical studies using d(ATATATATAT)₂ duplex oligonucleotides — a standard AT-rich minor groove binding substrate.
Cartalax and related Khavinson peptides showed measurable binding to these sequences, distinguishing them from peptides that act purely through extracellular or membrane receptor mechanisms.
This nuclear mechanism remains a subject of active research characterisation — it is the most mechanistically distinctive but also the least completely mapped aspect of Khavinson bioregulator pharmacology.

How Cartalax Works — The Five Core Mechanisms

Mechanism 1 — Senescence Suppression: p53, p16, p21 Downregulation

Cellular senescence is the state in which cells permanently exit the cell cycle — losing proliferative capacity, acquiring a pro-inflammatory secretory phenotype (SASP), and contributing to tissue ageing and dysfunction.
In cartilage, chondrocyte senescence is a primary driver of osteoarthritis: senescent chondrocytes produce high levels of MMP-9, IL-1β, and TNF-α while dramatically reducing collagen and proteoglycan synthesis.

The three principal molecular enforces of cellular senescence are p53 (tumour suppressor and apoptosis regulator), p16 (INK4a; CDK4/6 inhibitor that blocks cell cycle re-entry), and p21 (CIP1; CDK2 inhibitor enforcing G1/S cell cycle arrest).
Elevated levels of all three are the definitive signature of senescent cells.

Cartalax downregulates all three in published in-vitro and in-vivo models.
Khavinson et al. (2020) and Chalisova et al. confirmed that AED reduces p53, p16, and p21 expression in fibroblast cultures undergoing replicative senescence and in kidney organotypic culture systems.
This tri-factor senescence pathway suppression creates the molecular conditions for cells to re-enter the cell cycle and restore productive tissue function.

Mechanism 2 — Proliferation Activation: Ki-67, PCNA, and CD98hc Upregulation

Simultaneously with senescence suppression, Cartalax drives the opposing cellular programme: active proliferation.
Ki-67 is the gold-standard marker of cell proliferation — it is expressed exclusively in actively dividing cells and absent in G0 (quiescent) cells.
PCNA (Proliferating Cell Nuclear Antigen) is required for DNA polymerase delta function at replication forks — it is the molecular clamp that ensures DNA replication proceeds with fidelity during cell division.

Cartalax upregulates both Ki-67 and PCNA in fibroblast, chondrocyte, and kidney cell culture models.
This is particularly significant in aged cell populations where both markers typically decline: Cartalax appears to partially reverse the proliferative silence of aged cells, re-engaging DNA synthesis and cell division machinery.

CD98hc (also called 4F2hc; SLC3A2) is a transmembrane glycoprotein that forms the heavy chain of large neutral amino acid transporters.
It plays important roles in cellular regeneration, amino acid uptake, and cell-cell adhesion.
Its upregulation by Cartalax connects the proliferative programme to the nutrient-acquisition capacity needed to support actual cell growth and division.

Mechanism 3 — Longevity Sirtuin Activation: SIRT6 Upregulation

SIRT6 is a NAD⁺-dependent deacylase and ADP-ribosylase that plays critical roles in genomic stability, DNA double-strand break repair (through deacetylation of H3K9 and H3K56), telomere maintenance, and inflammatory gene suppression through NF-κB pathway regulation.
SIRT6 expression is consistently lower in senescent cells and in aged cartilage tissue compared to young tissue.

Cartalax upregulates SIRT6 in published fibroblast and chondrocyte models.
This is significant because SIRT6 upregulation opposes the senescence programme through multiple channels: it suppresses the p53-p21 axis that Cartalax is also targeting, reduces NF-κB-driven inflammatory gene expression (the same inflammatory genes that drive SASP in senescent chondrocytes), and enhances DNA repair capacity.

The SIRT6-p53 connection forms a mechanistic loop: Cartalax activates SIRT6, which then further suppresses p53 through chromatin-level silencing — amplifying and sustaining the anti-senescence effect beyond the direct p53 downregulation.
This makes the Cartalax mechanism self-reinforcing rather than single-step.

The SIRT6 upregulation also connects Cartalax to NAD⁺ biology.
NAD⁺ is the obligate substrate for all sirtuin enzymes.
Studying Cartalax alongside NAD⁺ supplementation in the same senescence model provides the combined SIRT6 activation (Cartalax) with the substrate availability (NAD⁺) required for sustained sirtuin function — a synergistic research design for investigating cellular longevity pathways.

Mechanism 4 — ECM Protection: MMP-9 Downregulation and Collagen II / Aggrecan Upregulation

Cartilage ECM degradation is the defining pathology of osteoarthritis.
MMP-9 (Matrix Metalloproteinase-9; Gelatinase B) is one of the primary enzymes responsible for degrading type IV collagen, aggrecan, and other structural ECM components.
In OA chondrocytes, MMP-9 is upregulated by IL-1β and TNF-α signalling, producing a catabolic spiral in which inflammatory cytokines drive ECM breakdown, further destabilising the tissue.

Cartalax downregulates MMP-9 in fibroblast and chondrocyte models — reducing the catabolic enzyme pressure on the matrix.
Simultaneously, it upregulates collagen type II (the primary structural collagen of hyaline cartilage) and aggrecan (the proteoglycan that provides cartilage its compressive resistance through water retention) — the two anabolic matrix components most critical for cartilage biomechanical function.

This MMP-9↓ / ColII↑ / Aggrecan↑ triad represents a systematic shift from a catabolic to an anabolic chondrocyte state.
For researchers studying OA disease mechanisms, Cartalax provides a tool compound for driving this state transition experimentally — analogous in outcome (but different in mechanism) to BPC-157‘s ECM and angiogenic repair activity or GHK-Cu‘s MMP-TIMP rebalancing.

Mechanism 5 — IGF-1 Upregulation (3.5–5.6× in Aging Cells)

One of the most quantitatively striking published findings for Cartalax is its effect on IGF-1 (Insulin-like Growth Factor 1) expression.
IGF-1 is produced locally by chondrocytes as well as systemically by the liver and, to a lesser extent, other tissues.
It is the primary anabolic growth factor for cartilage — it drives chondrocyte proliferation, collagen synthesis, proteoglycan synthesis, and survival through the IGF-1 receptor (IGF1R) → PI3K/Akt signalling cascade.

Khavinson laboratory studies report that Cartalax increases IGF-1 expression by 3.5–5.6× in aging fibroblast cell cultures.
This magnitude of IGF-1 upregulation in aged cells is exceptional — and it provides a mechanistic bridge between Cartalax and the GH/IGF-1 axis.

For research design, this IGF-1 connection makes Cartalax a logical pairing with GH axis compounds.
Sermorelin, Ipamorelin, and IGF-1 LR3 all work through the systemic GH/IGF-1 axis, while Cartalax may drive local chondrocyte IGF-1 expression through its transcriptional mechanism.
Studying their combination allows researchers to dissect local (Cartalax) vs systemic (GH axis compounds) IGF-1 contribution to cartilage repair independently.

Cartalax Research Evidence

Cartalax in the Khavinson Bioregulator Family

The Khavinson bioregulator family is the most extensive published series of tissue-specific short peptide regulators in gerontological research.
Each member targets a specific organ or tissue type through a conserved mechanism — DNA minor groove binding to tissue-specific regulatory gene sequences.

Understanding where Cartalax fits within this family helps researchers select the right combination of compounds for multi-tissue ageing or regenerative research panels.
The table below maps the most relevant family members.

Note the structural relationship between Cartalax (AED) and Epithalon (AEDG): Epithalon adds a C-terminal glycine to the Cartalax AED sequence.
This single glycine addition redirects biological targeting from cartilage/connective tissue (Cartalax) to the pineal gland/systemic telomere biology (Epithalon) — a remarkable example of how one amino acid addition can completely reorient tissue selectivity within the same peptide series.
Studying both compounds side-by-side is a natural SAR experiment within the Khavinson family.

What Is Cartalax Used for in Research?

Cartalax vs Related Joint, Cartilage, and Connective Tissue Research Compounds

Cartalax Pharmacokinetics and Handling

Cartalax Quality Control at SourceTides

Every batch of Cartalax Peptide from SourceTides undergoes these tests before release.
The sequence identity confirmation by MS is the critical QC checkpoint — distinguishing the Ala-Glu-Asp tripeptide (Cartalax, MW 333.29 Da) from structurally related sequences including Glu-Asp-Gly (related Khavinson fragment) or the tetrapeptide Ala-Glu-Asp-Lys.

Cartalax Regulatory Status

Peer-Reviewed References

Frequently Researched Alongside Cartalax

These compounds are most commonly studied alongside Cartalax in joint, cartilage, connective tissue, longevity, and anti-senescence research:

• Epithalon 10 mg — The closest Khavinson family member (AEDG vs Cartalax AED — one glycine extension); the essential SAR comparator; studied together in longevity panels combining cartilage regeneration (Cartalax) and telomere/systemic longevity (Epithalon); the AED→AEDG single-amino-acid SAR experiment is the most natural comparison in the Khavinson series
• Thymalin 10 mg — Khavinson thymic immune bioregulator; studied alongside Cartalax in multi-system longevity protocols combining cartilage/connective tissue restoration (Cartalax) and immune system rejuvenation (Thymalin); both produced in the same research programme from the same methodology
• Pinealon 10 mg — Khavinson CNS tripeptide bioregulator (EDR); studied alongside Cartalax in comprehensive multi-organ Khavinson longevity protocols combining CNS neuroprotection (Pinealon) and connective tissue regeneration (Cartalax)
• BPC-157 Vials — The primary tissue repair complement to Cartalax; BPC-157 restores vascular supply and drives physical repair via VEGFR2/NO/FAK; Cartalax activates the chondrocyte gene programme to produce new matrix; together they cover the vascular and biosynthetic arms of cartilage repair
• BPC-157 Capsules — Oral BPC-157 for systemic joint and connective tissue repair research; studied with Cartalax in OA protocols where systemic repair support (BPC-157) and local chondrocyte gene activation (Cartalax) are both required
• TB-500 (Thymosin Beta-4) — Actin-mediated repair and cell migration; studied with Cartalax in joint and tendon protocols combining cell migration and structural repair (TB-500) with chondrocyte matrix gene activation (Cartalax)
• GHK-Cu 50 mg Injectable — Broad-spectrum ECM repair via copper-enzyme activation; studied alongside Cartalax in ECM restoration panels comparing transcriptional gene regulation (Cartalax) with copper-enzyme matrix crosslinking (GHK-Cu)
• GHK-Cu Cosmetic Peptide — Topical/cosmetic-grade copper peptide; studied with Cartalax in skin and connective tissue research where topical collagen support (GHK-Cu cosmetic) complements systemic chondrocyte gene activation (Cartalax)
• AHK-Cu Peptide — Copper Tripeptide-3; TGF-β1 inhibition, VEGF, DPC survival; studied alongside Cartalax in joint inflammation research where TGF-β1 fibrosis suppression (AHK-Cu) and chondrocyte gene programme reactivation (Cartalax) are combined
• AOD-9604 Peptide — hGH fragment with preclinical cartilage proteoglycan data; studied with Cartalax in articular cartilage research comparing proteoglycan synthesis (AOD-9604) and chondrocyte ECM gene programme (Cartalax)
• NAD⁺ Injectable — Sirtuin substrate; NAD⁺ is the obligate cofactor for SIRT6 function; Cartalax upregulates SIRT6 expression while NAD⁺ provides the substrate for SIRT6 enzymatic activity — combined use provides both the enzyme (SIRT6 via Cartalax) and the fuel (NAD⁺) for the longevity sirtuin pathway in chondrocytes
• IGF-1 LR3 — Direct IGF-1R agonist; studied with Cartalax to dissect local (Cartalax-driven autocrine IGF-1 3.5–5.6×) vs systemic (IGF-1 LR3 direct receptor activation) IGF-1 pathways in chondrocyte anabolism
• Sermorelin 10 mg — GHRH agonist; studied with Cartalax in multi-axis cartilage repair protocols combining systemic GH/IGF-1 axis support (Sermorelin) and local chondrocyte transcriptional activation (Cartalax)
• Ipamorelin 10 mg — Selective GHS-R1a agonist; clean GH pulse without cortisol; studied with Cartalax in GH axis + cartilage gene biology research where systemic GH (Ipamorelin) combines with local chondrocyte IGF-1 induction (Cartalax)
• KPV Peptide 10 mg — NF-κB and MAPK inhibitor via PepT1 transport; studied alongside Cartalax in OA research combining direct NF-κB inflammatory suppression (KPV) and chondrocyte gene programme rescue (Cartalax) — addressing both the inflammatory and the regenerative arms of osteoarthritis biology simultaneously
• Selank Amidate 10 mg — IL-6 suppression and GABAergic anxiolytic; studied with Cartalax in joint inflammation panels where systemic IL-6 suppression (Selank) and local chondrocyte protection (Cartalax) are combined in inflammatory arthritis models
• Thymosin Alpha-1 — Immune modulation; studied with Cartalax in rheumatoid arthritis and immune-driven OA models where immune regulation (Thymosin Alpha-1) and cartilage gene programme support (Cartalax) are studied together
• LIPO-C Injectable — Multi-nutrient lipotropic; methionine methylation support; studied with Cartalax in metabolic-connective tissue health research where hepatic lipid metabolism (LIPO-C) and connective tissue gene regulation (Cartalax) are co-studied in metabolic syndrome OA models

Frequently Asked Questions